多灶性肿瘤性骨软化症一例报告  

Multiple phosphaturic mesenchymal tumors:a case report

作　　者：吴露露 裴育[1] 陈予龙[1] 倪奇 李一君 陈康[1] 巴建明[1] WU Lu-lu;PEI Yu;CHEN Yu-long;NI Qi;LI Yi-jun;CHEN Kang;BA Jian-ming(Department of Endocrinology,The First Medical Center of PLA General Hospital,Beijing 100853,China;Department of Endocrinology,Guangdong Provincial Hospital of Chinese Medicine,Guangzhou 510120,China)

机构地区：[1]解放军总医院第一医学中心内分泌科,北京100853 [2]广东省中医院内分泌科,广州510120

出　　处：《中华骨质疏松和骨矿盐疾病杂志》2023年第1期60-66,共7页Chinese Journal Of Osteoporosis And Bone Mineral Research

基　　金：国家自然科学基金青年科学基金(81300717);国家重点研发计划(2021YFC2501700)。

摘　　要：肿瘤性骨软化症是一种副肿瘤综合征,以低血磷、高尿磷、血钙及甲状旁腺素正常、1,25-二羟维生素D 3[1,25-dihydroxyvitamin D 3,1,25(OH)2D 3]正常或偏低、成纤维细胞生长因子23(fibroblast growth factor 23,FGF-23)升高为主要特征,经过手术治疗可获得根治。其多灶病例非常罕见。现报道多灶性肿瘤骨软化1例并文献复习,探讨该特殊情况下的处理策略。Tumor-induced osteomalacia is a paraneoplastic syndrome characterized by hypophosphatemia,renal phosphate wasting,normal blood calcium and parathyroid hormone,normal or low 1,25(OH)2D 3,and elevated fibroblast growth factor 23 levels.Its multifocal cases are very rare.A case of multiple phosphaturic mesenchymal tumors is reported and the literature is reviewed to explore the management strategy in this special situation.

关 键 词：肿瘤性骨软化 多灶 成纤维细胞生长因子23 诊治策略 

分 类 号：R681[医药卫生—骨科学]